Complete Genomics Again Rejects Illumina Overture | GenomeWeb

NEW YORK (GenomeWeb News) – Complete Genomics has again rejected Illumina's approach to acquire the firm.

Illumina aims to consummate a deal with Complete Genomics and scupper an agreement Complete Genomics already has signed to be acquired by BGI-Shenzhen for $3.15 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.